CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...